Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256814 | 0.87 | KMT2A (0.58) | EPHB3ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL954299 | 0.86 | EPHB3 (0.56) | EPHB3ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL12850522 | 0.86 | EPHB3 (0.60) | EPHB3ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL18766608 | 0.84 | EPHB3 (0.58) | EPHB3ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL2931119 | 0.83 | ALDH1A1 (0.54) | EPHB3ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL6223693 | 0.81 | MAPK1 (0.63) | EPHB3ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL12928390 | 0.81 | ALDH1A1 (0.47) | EPHB3ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL21819132 | 0.81 | ALDH1A1 (0.47) | EPHB3ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL3974420 | 0.81 | ALDH1A1 (0.69) | EPHB3ALDH1A1POLBGAAKMT2A | |
| SCHEMBL29690171 | 0.81 | EPHB3 (0.51) | EPHB3ALDH1A1POLBKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-3492461-A1 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | Shanghai Yingli Pharmaceutical Co. Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| EP-2678016-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | INTELLIKINE LLC | 2016-03-31 | — | — | US | disclosed |
| WO-2014151147-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012116237-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-08-30 | — | — | WO | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2011050245-A1 | BICYCLIC HETEROARYLS AS KINASE INHIBITORS | FENG YANGBO (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | EPHB3 3124/4885ALDH1A1 2379/4885POLB 2432/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | EPHB3 3124/4885ALDH1A1 2379/4885POLB 2432/4885 |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | MTOR, PIK3CA, AKT1 | EPHB3 3165/4885ALDH1A1 4335/4885POLB 3205/4885 |
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | EPHB3 4319/4885ALDH1A1 1687/4885POLB 4355/4885 |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | EPHB3 3124/4885ALDH1A1 2379/4885POLB 2432/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | EPHB3 2375/4885ALDH1A1 728/4885POLB 2653/4885 |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | EPHB3 3992/4885ALDH1A1 4784/4885POLB 3320/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | EPHB3 3021/4885ALDH1A1 4563/4885POLB 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.